EMMA 2016 | An update on immunotherapy for multiple myeloma in 2016
Ignacio M. Bermejo, Ignacio M. Bermejo, Ignacio Melero Bermejo, Jesús San Miguel and Paula Rodríguez-Otero
Jesús San Miguel, MD, PhD from the University Clinic of Navarra, Pamplona, Spain introduces the round table discussion on immunotherapy at the 2016 European Multiple Myeloma Academy (EMMA) in Madrid, Spain. Prof. San Miguel starts by introducing the subject of immunotherapy and commenting on the increased recognition of the importance of the immune system in hematological cancers. Prof. San Miguel is joined by by Ignacio Melero Bermejo, MD from the University Clinic of Navarra, Pamplona, Spain a leader in the field of immunotherapy, who explains the manipulation of the immune system for the treatment of cancer. Paula Rodríguez-Otero, MD, PhD from the University Clinic of Navarra, Pamplona, Spain, speaks about the success of elotuzumab in combination trials, as well as daratumumab and isatuximab, which have good responses in patients. The panel then explain how chimeric antigen receptor (CAR) therapies work and what their data in MM. To wrap up the discussion, Prof. San Miguel asks Dr Melero Bermejo so explain PDL-1 treatment and for Dr Rodríguez-Otero to talk about the current data on these agents for MM.
This programme has been supported by Celgene and Amgen through an unrestricted educational grant to the Video Journal of Hematological Oncology.
Get great new content delivered to your inboxSign up